Stocks and Investing Stocks and Investing
Wed, September 4, 2024

David Lebowitz Maintained (ASND) at Strong Buy with Decreased Target to $178 on, Sep 4th, 2024


Published on 2024-10-28 14:02:37 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Decreased Target from $193 to $178 on, Sep 4th, 2024.

David has made no other calls on ASND in the last 4 months.



There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $140 on, Thursday, May 16th, 2024


These are the ratings of the 3 analyists that currently disagree with David


  • Kelly Shi of "Jefferies" Maintained at Strong Buy with Increased Target to $196 on, Tuesday, August 13th, 2024
  • Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $195 on, Tuesday, August 13th, 2024
  • Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $200 on, Friday, May 31st, 2024
Contributing Sources